Physician profile
Sara E Raymond
NPI 1902255490
$288,128.14
in general payments reported to CMS, 2019-2025
10 companies · $36.32 in 2025
The $36.32 reported for 2025 was less than what a typical Pediatrics (Nurse Practitioner) provider received nationally (typical 2025 total: $93.49).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $58.50 · 2022: $66.95 · 2023: $219K · 2024: $69K · 2025: $36.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $288K · Food and Beverage: $238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $287,765.00 |
| Food and Beverage | $237.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $287,890.00 | 2023-2024 | Xifaxan |
| Abbott Laboratories | $50.47 | 2022-2025 | Cardiomems |
| Dexcom, INC. | $44.98 | 2021-2022 | |
| Medtronic, INC. | $31.39 | 2023 | Inpen Smart Insulin Delivery System |
| Tolmar Pharmaceuticals, INC. | $26.63 | 2021-2022 | |
| Insulet Corporation | $23.72 | 2022 | |
| Biomarin Pharmaceutical INC. | $16.04 | 2024 | |
| Eton Pharmaceuticals, INC. | $15.97 | 2021 | |
| Novo Nordisk INC | $14.85 | 2023 | Sogroya |
| Tolmar, INC. | $14.09 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Raymond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.